vs

Side-by-side financial comparison of CABOT CORP (CBT) and Nomad Foods Ltd (NOMD). Click either name above to swap in a different company.

CABOT CORP is the larger business by last-quarter revenue ($849.0M vs $834.9M, roughly 1.0× Nomad Foods Ltd). On growth, Nomad Foods Ltd posted the faster year-over-year revenue change (-2.6% vs -11.1%). Nomad Foods Ltd produced more free cash flow last quarter ($272.4M vs $57.0M).

Cabot Corporation is an American specialty chemicals and performance materials company headquartered in Boston, Massachusetts. The company operates in over 20 countries with 36 manufacturing plants, eight research and development facilities, and 28 sales offices.

Nomad Foods is the largest frozen food company in Europe, whose popular brands include Birds Eye, Ledo, Iglo, Findus, and Frikom. The company manufactures, sells and distributes a range of frozen food products across 22 European markets, with its headquarters in the United Kingdom. The most popular products in Nomad Foods’ portfolio include fish fingers, creamed spinach, peas and chicken. Nomad Foods is listed on the New York Stock Exchange trading under the ticker “NOMD”.

CBT vs NOMD — Head-to-Head

Bigger by revenue
CBT
CBT
1.0× larger
CBT
$849.0M
$834.9M
NOMD
Growing faster (revenue YoY)
NOMD
NOMD
+8.5% gap
NOMD
-2.6%
-11.1%
CBT
More free cash flow
NOMD
NOMD
$215.4M more FCF
NOMD
$272.4M
$57.0M
CBT

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
CBT
CBT
NOMD
NOMD
Revenue
$849.0M
$834.9M
Net Profit
$73.0M
Gross Margin
24.9%
25.6%
Operating Margin
15.2%
9.1%
Net Margin
8.6%
Revenue YoY
-11.1%
-2.6%
Net Profit YoY
-21.5%
EPS (diluted)
$1.37

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBT
CBT
NOMD
NOMD
Q4 25
$849.0M
$834.9M
Q3 25
$899.0M
Q2 25
$923.0M
Q1 25
$936.0M
Q4 24
$955.0M
$856.9M
Q3 24
$1.0B
Q2 24
$1.0B
Q1 24
$1.0B
Net Profit
CBT
CBT
NOMD
NOMD
Q4 25
$73.0M
Q3 25
$43.0M
Q2 25
$101.0M
Q1 25
$94.0M
Q4 24
$93.0M
$55.5M
Q3 24
$137.0M
Q2 24
$109.0M
Q1 24
$84.0M
Gross Margin
CBT
CBT
NOMD
NOMD
Q4 25
24.9%
25.6%
Q3 25
24.5%
Q2 25
26.4%
Q1 25
25.7%
Q4 24
24.6%
28.5%
Q3 24
24.0%
Q2 24
25.2%
Q1 24
24.1%
Operating Margin
CBT
CBT
NOMD
NOMD
Q4 25
15.2%
9.1%
Q3 25
15.2%
Q2 25
18.1%
Q1 25
17.3%
Q4 24
16.2%
11.5%
Q3 24
15.0%
Q2 24
16.9%
Q1 24
15.3%
Net Margin
CBT
CBT
NOMD
NOMD
Q4 25
8.6%
Q3 25
4.8%
Q2 25
10.9%
Q1 25
10.0%
Q4 24
9.7%
6.5%
Q3 24
13.7%
Q2 24
10.7%
Q1 24
8.2%
EPS (diluted)
CBT
CBT
NOMD
NOMD
Q4 25
$1.37
Q3 25
$0.80
Q2 25
$1.86
Q1 25
$1.69
Q4 24
$1.67
Q3 24
$2.41
Q2 24
$1.94
Q1 24
$1.49

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBT
CBT
NOMD
NOMD
Cash + ST InvestmentsLiquidity on hand
$230.0M
Total DebtLower is stronger
$2.5B
Stockholders' EquityBook value
$1.6B
$2.7B
Total Assets
$3.8B
$6.8B
Debt / EquityLower = less leverage
0.92×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBT
CBT
NOMD
NOMD
Q4 25
$230.0M
Q3 25
$258.0M
Q2 25
$239.0M
Q1 25
$213.0M
Q4 24
$183.0M
Q3 24
$223.0M
Q2 24
$197.0M
Q1 24
$206.0M
Total Debt
CBT
CBT
NOMD
NOMD
Q4 25
$2.5B
Q3 25
$1.1B
Q2 25
Q1 25
Q4 24
$2.4B
Q3 24
$1.1B
Q2 24
Q1 24
Stockholders' Equity
CBT
CBT
NOMD
NOMD
Q4 25
$1.6B
$2.7B
Q3 25
$1.6B
Q2 25
$1.5B
Q1 25
$1.4B
Q4 24
$1.4B
$2.9B
Q3 24
$1.4B
Q2 24
$1.3B
Q1 24
$1.4B
Total Assets
CBT
CBT
NOMD
NOMD
Q4 25
$3.8B
$6.8B
Q3 25
$3.8B
Q2 25
$3.8B
Q1 25
$3.8B
Q4 24
$3.6B
$6.9B
Q3 24
$3.7B
Q2 24
$3.6B
Q1 24
$3.6B
Debt / Equity
CBT
CBT
NOMD
NOMD
Q4 25
0.92×
Q3 25
0.70×
Q2 25
Q1 25
Q4 24
0.82×
Q3 24
0.75×
Q2 24
Q1 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBT
CBT
NOMD
NOMD
Operating Cash FlowLast quarter
$126.0M
$357.2M
Free Cash FlowOCF − Capex
$57.0M
$272.4M
FCF MarginFCF / Revenue
6.7%
32.6%
Capex IntensityCapex / Revenue
8.1%
10.2%
Cash ConversionOCF / Net Profit
1.73×
TTM Free Cash FlowTrailing 4 quarters
$401.0M
$1.3B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBT
CBT
NOMD
NOMD
Q4 25
$126.0M
$357.2M
Q3 25
$219.0M
Q2 25
$249.0M
Q1 25
$73.0M
Q4 24
$124.0M
$470.2M
Q3 24
$204.0M
Q2 24
$207.0M
Q1 24
$176.0M
Free Cash Flow
CBT
CBT
NOMD
NOMD
Q4 25
$57.0M
$272.4M
Q3 25
$155.0M
Q2 25
$188.0M
Q1 25
$1.0M
Q4 24
$47.0M
$383.5M
Q3 24
$112.0M
Q2 24
$155.0M
Q1 24
$133.0M
FCF Margin
CBT
CBT
NOMD
NOMD
Q4 25
6.7%
32.6%
Q3 25
17.2%
Q2 25
20.4%
Q1 25
0.1%
Q4 24
4.9%
44.8%
Q3 24
11.2%
Q2 24
15.3%
Q1 24
13.1%
Capex Intensity
CBT
CBT
NOMD
NOMD
Q4 25
8.1%
10.2%
Q3 25
7.1%
Q2 25
6.6%
Q1 25
7.7%
Q4 24
8.1%
10.1%
Q3 24
9.2%
Q2 24
5.1%
Q1 24
4.2%
Cash Conversion
CBT
CBT
NOMD
NOMD
Q4 25
1.73×
Q3 25
5.09×
Q2 25
2.47×
Q1 25
0.78×
Q4 24
1.33×
8.47×
Q3 24
1.49×
Q2 24
1.90×
Q1 24
2.10×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBT
CBT

Reinforcement Materials$520.0M61%
Performance Chemicals$300.0M35%
Shipping And Handling$25.0M3%
Other Products And Services$4.0M0%

NOMD
NOMD

Segment breakdown not available.

Related Comparisons